Circular RNA circSIPA1L1 Contributes to Osteosarcoma Progression via the miR-411-5p/RAB9A Axis

Yining Xu
Shaoxing University Medical College

Teng Yao
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Haonan Ni
Kunming Medical University

Rujie Zheng
Wenzhou medical university

Kangmao Huang
Sir run run shaw Hospital

Yizhen Huang
Sir run run shaw hospital

Jun Gao
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Di Qiao
Shaoxing University Medical College

Shuying Shen
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Jianjun Ma (✉ sealteam@zju.edu.cn)
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Research

Keywords: Circular RNA, Osteosarcoma, circSIPA1L1, miR-411-5p, RAB9A

DOI: https://doi.org/10.21203/rs.3.rs-125943/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Recently, various studies have identified circular RNAs (circRNAs) to play a significant role in tumorigenesis, thereby showing potential as novel tumor biomarkers. circSIPA1L1 is a new-found circular RNA formed by back-splicing of SIPA1L1 and is found increased in osteosarcoma (OS). Nevertheless, the specific functions of circSIPA1L1 in OS remain unknown.

Methods

In the present study, circSIPA1L1 was obtained from a previously reported circRNA microarray (GSE96964) in the GEO database. Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to assess the mRNA level of circSIPA1L1 in OS cell lines and tissue samples. Bioinformatics analysis, luciferase reporter assays, real-time PCR, RNA pull-down assays and RNA immunoprecipitation (RIP) were employed to verify the binding of circSIPA1L1 with miR-411-5p. Xenograft tumor models were established to identify the role of circSIPA1L1 in vivo. A series of in-vitro experiments, such as western blotting, colony formation, transwell assays and anoikis assay were employed to confirm the relationship across circSIPA1L1, miR-411-5p, and RAB9A.

Results

Our study confirmed circSIPA1L1 to be upregulated in both human OS samples and OS cell lines. Mechanistically, circSIPA1L1 could serve as a miR-411-5p molecular sponge to increase RAB9A expression, which was confirmed to be a tumor promoter mediating carcinogenesis. Silencing of circSIPA1L1 attenuated the vitality, invasion, migration and proliferation of OS cell lines both in vivo and in vitro. miR-411-5p inhibition or RAB9A overexpression reversed the anti-tumor effects caused by circSIPA1L1 knockdown.

Conclusion

Briefly, circSIPA1L1 acts as a driver gene in OS and could initiate OS tumorigenesis via the miR-411-5p/RAB9A axis, which might become a potential therapeutic biomarker for OS treatment.

Background

Osteosarcoma (OS), a neoplasm with high aggressiveness and formidable distant metastatic characteristics, is the third most prevalent and lethal primary bone malignancy across children, youth, and adolescents(1). At present, the major therapeutic strategy proposed for patients suffered from OS is surgical resection and polychemotherapy in combination (2). Nevertheless, owing to the rapid proliferation, high metastatic potential, and multi-drug resistance of OS, the prognosis of patients with metastatic OS remains poor(3). According to previous reports, while the long-term overall survival of patients suffered from OS with no metastasis is greater than 60%, the five-year survival rate of patients in
an advanced disease stage could be as low as 20%, owing to distant metastasis and recurrence(4, 5). Therefore, investigation of the underlying molecular mechanisms and identification of highly sensitive and clinically relevant markers of OS are urgently required for early diagnosis and development of more effective therapeutic measures.

As an attractive class of non-coding endogenous RNA transcript, circular RNA (circRNA) is being extensively investigated due to its unique circular structure formed by non-canonical splicing of linear premRNAs(6, 7). circRNA is characterized by lacking 5’ caps and 3’ polyadenylated tails, and is equipped with covalently closed continuous loop structure, which make it highly stable and resistant to degradation by endonucleases(8). In recent years, studies have shown that circRNAs exert significant influence on multiple human diseases by interacting with RNA-binding proteins, sponging microRNA (miRNA), and regulating transcription and protein translation(9–12). With advancement in high-throughput sequencing and bioinformatics approaches, a growing number of circRNAs have been demonstrated to be highly expressed in multiple human cancers, and to play crucial roles in a wide variety of biological processes in cancer(13, 14). Nevertheless, the specific function and mechanisms of circSIPA1L1 in OS have not been adequately elucidated.

miRNAs form another class of non-coding RNAs that have been broadly investigated(15). Substantial studies have identified the vital role of miRNAs in regulating various kinds of biological functions, including gene expression, cell proliferation, cell cycle, apoptosis, and differentiation(16, 17). While miR-411-5p has been discovered to be firmly correlated with prognosis in hepatocellular carcinoma, few reports have identified its role in OS(18).

Originated from the Rab GTPase family, RAB9A is essential to the recycling of mannitose 6-phosphate receptors from late endosomes to trans-Golgi network(19). RAB9A is also involved in lysosomal biogenesis and late endosomal morphology(20). RAB9A is known to be highly detected in breast cancer samples and is tightly linked to the biological progression of breast cancer(21). But whether it could be targeted by circSIPA1L1 and miR-411-5p in OS needs to be explored further.

In this study, we confirmed circSIPA1L1 from exons 5 and 7 of the SIPA1L1 gene and RAB9A as oncogenes in OS. The expression of circSIPA1L1 was upregulated in OS, although the mRNA level of SIPA1L1 remained unchanged. In conclusion, circSIPA1L1 remarkably increased the proliferation and metastasis of OS through the miR-411-5p/RAB9A signaling pathways.

**Methods**

**Clinical samples**

10 pairs of fresh frozen chondroma tissue samples and OS tissue samples from 20 untreated patients before surgery (10 for each group), were acquired from Sir Run Run Shaw Hospital between March 2019 and March 2020. All patients offered written informed consent approving the samples for research.
project was authorized by the Ethics Committee of Sir Run Run Shaw Hospital. All samples were stored at liquid nitrogen until RNA extraction.

**Cell culture**

Normal osteoblast cell hFOB1.19 and human osteosarcoma cell lines, including 143B, SJSA-1, HOS, MG-63, U2OS were purchased from ATCC. All the cell lines were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). All the cells were identified to be mycoplasma-free and were kept at 37°C with 5% CO₂.

**Cell transfection**

Short hairpin RNA targeting (siRNAs) targeting circSIPA1L1(5'-AGGGAGAAAGCATGGGATT-3'), miR-411-5p mimics (5'-UAGUAGACCGUAUAGCGUACG-3') and miR-411-5p inhibitors(5'-CGUACGCUAUACGGUCUUUA-3'), RAB9A overexpression plasmid and their negative controls were obtained from RiboBio (Guangzhou, China). All above vectors were transfected using Lipofectamine 3000 (Thermo Fisher Scientific, IL, USA). The efficiency of transfection was evaluated using qRT-PCR after transfection for 48–72 h.

**RNA isolation, RNase R digestion, and qRT-PCR**

Total RNAs were extracted using Trizol reagent (Invitrogen) according to the manufacture protocols. For RNase R treatment, 2 mg of total RNA deriving from osteosarcoma cell lines was treated with or without RNase R (Epicentre Technologies) for 15 min at 37°C. To synthesize the complementary DNA (cDNA), a PrimerScript RT reagent kit (TaKaRa) was employed. qRT-PCR were subsequently conducted using SYBR Premix ExTaq II (TaKaRa). GAPDH was served as a normalization for mRNA and circRNA analyses. U6 was employed as an internal standard control for miRNA analyses. The primer sequences used in research were as follows: hsa_circSIPA1L1_006 (Forward: 5'-CCAGCTTGAAACGGTCACAGA-3'; Reverse: 5'-GCGCCGCATGTGAATATCATC -3'); SIPA1L1 (Forward: 5'-CCAGCTTGAAACGGTCACAGA-3'; Reverse: 5'-GCGCCGCATGTGAATATCATC -3'); GAPDH (Forward, 5'-TCAAGATCATCAGCAATGCC-3'; Reverse: 5'-CGATACCAAAGTTGTCATGGA-3'); Beta Actin(Forward: CATGTACGTTGCTATCCAGGC-3'; Reverse: 5'-CTCCTTAATGTCACCGACATG-3'); miR-411-5p (Forward: 5'-CCGGAACCCCCTCCTTACTC-3'; Reverse: 5'-AATGGGATGTGTCAGCAGGAGA-3'); U6 (Forward, 5'-CTCCTTCCAGTTCGCTATCG-3'; Reverse: 5'-AACGCTTCACGAATTTGCGT-3'); RAB9A((Forward, 5'-AGGGACACGGCGACTATC; Reverse: 5'-TCTGACCTATCCGTTAGCA-3').

**Xenograft tumorigenesis**

4-week-old nude mice(male)were prepared for the xenograft tumor models. 4 × 10⁶ 143B stable cells in total were suspended in phosphate-buffered saline (PBS) and were injected subcutaneously. Tumor volumes were calculated with formula listed below: volume = (width × length)²/2. Thirty days after treatment, the nude mice were sacrificed, and the weight and volume of their tumors were measured.

**Fluorescence in situ hybridization (FISH)**
Cy3-labeled circSIPA1L1 probes were purchased from RiboBio. A Fluorescent In Situ Hybridization Kit was employed to detect the signals of the probes following the kit instructions. The images were captured using Nikon A1Si Laser Scanning Confocal Microscope (Japan).

**RNA immunoprecipitation (RIP)**

RIP assays were employed utilizing the Magna RIP Kit (Millipore). Sh-NC or sh-circSIPA1L1 was stably transfected into 143B cells. Subsequently, 143B cells were lysed using RIP lysis buffer supplemented with RNase inhibitors and protease inhibitors. Then IgG antibody or anti-Ago2 coated beads (Millipore) were used to incubate with lysates with rotation overnight at 4 °C. The lysates were treated with proteinase K buffer, followed by RNA extraction. Purified RNA was acquired and reversely transcribed. Finally, qRT-PCR was performed to detect the abundance of circSIPA1L1.

**Pull-down assay**

In brief, $1 \times 10^7$ 143B and HOS cells were treated with lysis buffer. C-1 magnetic beads were incubated with circSIPA1L1 probe for 2 h at 25 °C to acquire probe-coated beads. After that, oligo probe or circSIPA1L1 probe was incubated with the cell lysates overnight at 4 °C, respectively. The RNA compounds binding to the magnetic beads were washed 4 times with washing buffer. After purification, RT-PCR and qRT-PCR were employed to detect the expression levels of candidate miRNAs.

**Luciferase reporter assay**

HEK-293 cells were seeded into 96-well plate and cultured overnight. Subsequently, the cells were cotransfected with luciferase reporter plasmid mixtures using LipofectamineTM2000 reagent. After 24 h, the luciferase activity was detected with a dual-luciferase reporter assay system (Promega).

**Western blotting analysis and antibodies**

RIPA Lysis Buffer with 1% protease inhibitor (Fudebio) was utilized to lyse stable transfected OS cells. Subsequently, the concentrations of protein were evaluated using a BCA Protein Assay Kit (Beyotime). The protein samples were separated using 10% SDS-PAGE by electrophoresis, and then were transferred onto a PVDF membrane (Millipore) and blocked with 5% non-fat milk powder in TBST for 2 h. Specific primary antibodies were incubated with the membranes at 4 °C overnight. After washing with TBST, the membranes were treated with a secondary antibody (Fudebio) for 1 h. Finally, an ECL substrate kit (Thermo Scientific) was employed to visualize the immunoblots results.

**Wound-healing assay**

Transfected OS cells were cultured in 6-well cell culture plates and cultured overnight until 90% confluence, and the confluent cell layer were scrape a straight scratch with 200 µl pipette tips. Representative images of cell migration from specific scratched positions were captured by microscopy at 0 and 24 h after injury.

**Colony formation assay**
Briefly, 143B and HOS cells (5 × 10^2 per well) were seeded into a 12-well cell culture dishes and cultured for 10 days. After washing with PBS twice, the colonies were fixed using 4% paraformaldehyde for 15 min and stained with 0.1% crystal violet for another 15 min at 37 °C. The colonies were counted and photographed using a microscope.

**Migration-related assays**

Regarding to transwell migration assay, the transfected 143B and HOS cells were cultured in 200 µL of serum-free medium and added into the upper chambers (8 µm, Corning, NY, USA). While the lower chambers were supplemented with 500 µl fresh culture medium containing 10% FBS. Invasion assays were performed in the same procedure except that the membrane was covered with Matrigel. After incubating for 24 h, the migrated and invaded cells were fixed and subjected to 0.1% crystal violet solution staining. The images were captured using a microscope depending on at least five random fields.

**Apoptosis analysis**

Apoptosis analysis was conducted using an AnnexinV-FITC/PI double staining kit (BD Biosciences). Briefly, the transfected OS cells were harvested and subjected to resuspension in 1 × Binding Buffer and then treated with Annexin V-FITC/PI according to the kit instructions. After incubating for 15 min, a flow cytometer (BD Biosciences) was employed to detect the Apoptosis of the cells.

**Statistical analyses**

Statistical analyses were carried out using SPSS 20 software. The experimental data were evaluated with unpaired Student's t-test. P values less than 0.05 indicated that the data were statistically significant.

**Results**

**circSIPA1L1 was expressed relatively abundantly in OS cell lines and tissues and mainly localized in the cytoplasm**

First, we downloaded a microarray expression dataset (GSE96964) from the GEO database, comparing circRNAs in hFOB1.19 cells with those in OS cells to select the differentially expressed circRNAs. We discovered circSIPA1L1 (also called circ_0032462) to be highly expressed in a series of OS cells than in normal osteoblast cell line (Fig. 1A). To determine the specific function of circSIPA1L1 in OS progression, 10 pairs of chondroma and OS tissue samples were collected to measure the expression level of circSIPA1L1 using qRT-PCR. Results indicated the abundance of circSIPA1L1 to be remarkably enhanced in OS tissue samples compared with chondroma tissue samples (Fig. 1B). We next validated using qRT-PCR that the abundance of circSIPA1L1 was notably increased in OS cell lines (U20S, 143B, HOS, and MG-63) in comparison with hFOB1.19 cells. Among the various OS cell lines, 143B and HOS cells showed significant increase in circSIPA1L1 expression (Fig. 1C). Divergent primers of circSIPA1L1 were designed, and head-to-tail splicing was identified in the RT-PCR-amplified product of circSIPA1L1 (Fig. 1D). Stability is a significant feature of circRNAs that differentiates them from mRNAs. To verify the stability of
circSIPA1L1, RNase R was used in the assay. circSIPA1L1 exhibited high tolerance to RNase R treatment while the levels of linear form of SIPA1L1 were significantly decreased upon exposure to RNase R (Fig. 1E). To eliminate the possibility of trans-splicing or genomic rearrangements generating head-to-tail splicing, gDNA and cDNA were acquired from 143B and HOS cells, followed by DNA electrophoresis. While circSIPA1L1 could only be detected from cDNA, SIPA1L1 could be detected from both gDNA and cDNA (Fig. 1F). FISH assays indicated circSIPA1L1 to be predominantly localized in the cytoplasm (Fig. 1G).

**circSIPA1L1 knockdown inhibited the invasion, migration, proliferation, and survival ability of OS cells in vitro**

To identify the potential role of circSIPA1L1 in OS cells, circSIPA1L1 small hairpin RNA (shRNA), which could silence the circSIPA1L1 expression, was transfected into OS cells. The sh-circSIPA1L1 product specifically aimed the junction site of circSIPA1L1 and constructed stable circSIPA1L1-silencing OS cells. Figure 2A demonstrates that the expression of circSIPA1L1 was notably decreased by sh-circSIPA1L1 while its mRNA level remained unchanged. Accordingly, the migration and invasion capabilities of OS cell lines decreased sharply upon transfection with sh-circSIPA1L1, as observed by wound-healing assay (conducted subsequently; Fig. 2B and C). The results of CCK-8 assay indicated circSIPA1L1 knockdown to remarkably compromise cell viability. Consistently, as shown in Fig. 2E, circSIPA1L1 silencing impaired the proliferation capacity of OS cells. Flow cytometric assays were performed to demonstrate the impact of circSIPA1L1 silencing on the survival ability of OS cells. Taken together, the findings indicated that circSIPA1L1 exerted a significant influence on the biological behavior of OS cells in vitro.

**circSIPA1L1 functioned as a molecular sponge for miR-411-5p in OS**

Previous reports suggested that circRNAs could serve as sponges for their downstream miRNAs to regulate gene expression, which could further alter cancer progression. As shown above, circSIPA1L1 was identified to predominantly locate in the cytoplasm, representing striking stability. We hypothesized that circSIPA1L1 might serve as an efficient sponge for miR-411-5p. To check the hypothesis, we subsequently performed RIP assay for AGO2 in 143B cells. Results showed endogenous circSIPA1L1 pulled down from AGO2 antibodies to be remarkably enriched while it was less so in the group where circSIPA1L1 was stably silenced, hence indicating that circSIPA1L1 interacted and bound to miRNAs through AGO2 protein (Fig. 3A). To identify whether circSIPA1L1 functioned as an miRNA sponge in 143B and HOS cells, we utilized three biological databases (RNAhybrid miRanda, and TargetScan, and) to predict the underlying target miRNAs of circSIPA1L1. Sixteen candidate miRNAs were picked out by overlapping the prediction diagrams (Fig. 3B). Next, we designed a biotinylated circSIPA1L1 probe and conducted a pull-down assay, based on which four probable miRNAs with greatly increased fold-changes were selected in both 143B and HOS cells (Fig. 3C and D). A luciferase assay was subsequently performed, and the binding of four miRNAs was verified (Fig. 3E).
An apoptosis experiment was conducted to explore the specific role of miRNAs in OS cells. Figure 3F indicates that among the multiple miRNAs, overexpression of miR-411-5p caused the highest apoptotic rates in both 143B and HOS cells. Bioinformatic analysis revealed an miRNA response element that circSIPA1L1 shares with miR-411-5p (Fig. 3G). Subsequently, we mutated this miRNA response element using a luciferase reporter including circSIPA1L1 in the 3’-untranslated region (3’-UTR). We discovered the luciferase activity of mut (mutant) to be remarkably higher than that of the wild-type (WT) reporter (Fig. 3H), hence indicating the ability of miR-411-5p to bind to circSIPA1L1 directly. Collectively, the above results indicated miR-411-5p to be sponged by circSIPA1L1.

**Knockdown of miR-411-5p reversed the sh-circSIPA1L1-induced attenuation of malignant behavior of OS cells**

A xenograft model was constructed to explore the roles of circSIPA1L1 and mir-411-5p in vivo. 143B cells, stably expressed with negative control or circSIPA1L1-deficient or co-expressed with sh-circSIPA1L1 and the mir-411-5p sponge were established and subcutaneously injected into nude mice. The tumors harvested from the circSIPA1L1-knockdown group were found to be distinctly inferior, in both volume and weight, to those from the control group. Intriguingly, the miR-411-5p sponge remarkably reversed the circSIPA1L1-induced antitumor effects on volume and weight (Fig. 4A–C). Expression of miR-411-5p was detected in 10 pairs of OS and chondroma tissue samples by qRT-PCR. Results indicated the expression levels of miR-411-5p to be notably reduced in the OS tissue compared with that in the chondroma tissue (Fig. 4D). We further performed rescue experiments to investigate whether circSIPA1L1 could bind and interact with mir-411-5p to amplify malignant behavior in OS. sh-circSIPA1L1 and mir-411-5p sponges were co-transfected in both 143B and HOS cells. Attenuation of cell proliferation, migration, invasion, viability, and survival ability was blocked by the exogenous knockdown of miR-411-5p, as shown by the results of wound-healing, Matrigel invasion, transwell migration, CCK-8, colony formation, and apoptosis experiments. These results together demonstrated that circSIPA1L1 mediates OS progression by sponging miR-411-5p, both in vivo and in vitro.

**miR-411-5p targeted RAB9A in OS**

After identifying that miR-411-5p could partly restore the impairment of malignant tumor phenotype caused by sh-circSIPA1L1. We further explore the specific mechanism of miR-411-5p in OS progression. We selected TargetScan, miRDB, and miRWalk databases to predict the possible targets of miR-411-5p. Five genes (LRRC57, RAB9A, PFN1, RNF149, and EIF3J) were selected by overlapping the prediction results (Fig. 5A). Expression of these 5 genes was detected in 143B and HOS cells transfected with sh-circSIPA1L1. qRT-PCR results indicated circSIPA1L1-knockdown to notably decrease the expression of RAB9A in both 143B and HOS cells (Fig. 5B). We further explored whether miR-411-5p could directly interact with RAB9A. The RAB9A 3’-UTR possessed sequences complementary to the miR-411-5p seed sequence (Fig. 5C). Therefore, we generated 3’-UTR sensors and cotransfected 293T cells with miR-411-5p mimics. Reduced luciferase activity due to the RAB9A 3’-UTR was detected using miR-411-5p mimics. Accordingly, much higher luciferase activity was observed using mutated forms of the RAB9A 3’-UTR.
qRT-PCR and western blotting were performed to investigate whether RAB9A could be directly targeted by miR-411-5p. As expected, miR-411-5p overexpression in cotransfected 143B and HOS cells decreased RAB9A expression at both mRNA and protein levels, whereas miR-411-5p inhibition in the cells showed the opposite effects on RAB9A expression at both mRNA and protein levels (Fig. 5E and F). Together, the results suggested RAB9A to be an oncogene in OS and to possibly be targeted by miR-411-5p directly.

**circSIPA1L1 mediated OS progression via RAB9A**

To further identify whether circSIPA1L1 contributes to OS progression through RAB9A, we established an RAB9A overexpression plasmid and transfected it into circSIPA1L1-deficient OS cells. qRT-PCR data indicated RAB9A to partly reverse the decrease in RAB9A expression resulting from circSIPA1L1 silencing (Fig. 6A). Western blotting confirmed this effect at the protein level. Intriguingly, change in E-cadherin and N-cadherin expressions also confirmed the crucial role of RAB9A in recovering the loss of EMT caused by circSIPA1L1-deficiency in cells (Fig. 6B). To investigate whether RAB9A was able to recover the phenotypes of circSIPA1L1-knockdown OS cells, rescue experiments were performed. Cell migration and invasion of OS cells were found to be significantly restored by RAB9A (Fig. 6C and D). In addition, increasing RAB9A levels abrogated the impairment of cell viability and colony-forming ability of OS cells caused by sh-circSIPA1L1 (Fig. 6E and F). Moreover, apoptosis assay revealed OS cell survival ability to be ameliorated by the overexpression of RAB9A (Fig. 6G). Taken together, the results indicated the regulation of OS progression by circSIPA1L1 via targeting RAB9A.

**Discussion**

As a newly emerging member of the non-coding RNA family, circRNAs have gained extensive attention recently, owing to the advances in bioinformatics approaches and widespread use of transcriptome sequencing(22, 23). Accumulating research has suggested that circRNAs are involved in a variety of disease processes owing to their unique characteristics, such as high abundance, structural stability, and conservation across species(24, 25). Besides the abnormal activation of oncogenes and inactivation of antioncogenes, circRNAs also exert a significant effect on the genesis, proliferation, and metastasis of tumors(26). Nevertheless, the detailed functions and mechanisms of these circRNAs still remain unclear. In this research, we concentrated on the specific functions and potential mechanisms of circSIPA1L1, which is enhanced in OS cell lines and tissues.

circSIPA1L1 originates from the signal induced proliferation associated 1 like 1 (SIPA1L1) gene(27). Previous studies had confirmed SIPA1L1 to be strongly correlated with colorectal cancer and hereditary nonpolyposis(28, 29). In our current study, expression of circSIPA1L1 was confirmed to be upregulated in both OS cell lines and tissue. In addition, the stability of circSIPA1L1 was determined after treatment with RNase R. Silencing of circSIPA1L1 significantly attenuated the malignant behavior of OS cells, as determined by loss-of-function assays. Collectively, these findings suggested that circSIPA1L1 plays an important part in the pathogenesis of OS.
circRNAs are acknowledged to be capable of regulating gene expression through a variety of regulatory models, such as sponging microRNA, interacting with RNA-binding proteins, and contributing to protein translation. Among the multiple regulatory models, microRNA sponging is the most classical and most frequently reported. circRNAs, as ceRNAs, possess miRNA-binding sites and can serve as natural miRNA inhibitors to regulate gene expression. For instance, the CDR1/ciRS-7 circRNA harbors over 70 conserved binding sites specifically for miR-7 and is able to alter the expression of miR-7 target gene as an miR-7 sponge(30). Similarly, has_circ_0030998 downregulates miR-558 expression as a sponge to suppress lung cancer tumorigenesis(31). Other studies by our group had also demonstrated that circSIPA1L1 exhibits post-transcriptional regulation as miR-411-5p sponge to recover the expression of RAB9A, which is also targeted by miR-411-5p. In the current study, 16 candidate miRNAs targeted by circSIPA1L1 were selected using bioinformatic analysis. The interactions between circRNAs and miRNAs were confirmed by RIP and luciferase assays. Upon further investigation, miR-411-5p was found to exhibit the strongest binding ability with circSIPA1L1 among the various candidate miRNAs. The rescue assays performed subsequently confirmed the effects of miR-411-5p on OS both in vivo and in vitro. In addition, our study indicated circSIPA1L1 to mediate the biological processes of OS via the miR-411-5p/RAB9A axis. RAB9A is a subtype of RAB9, which plays a significant role in the biological process of breast cancer cells; silencing of RAB9 can attenuate the malignant phenotypes of melanoma cells. As far as I know, this is the first report of RAB9A being identified as an oncogene in OS using loss-of-function assays and rescue experiments. In summary, our findings demonstrated that circSIPA1L1 promotes OS progression and metastasis by regulating RAB9A expression and sponging miR-411-5p.

In the current study, we identified the role of circSIPA1L1/miR-411-5p/RAB9A axis in OS progression. Detailed mechanisms underlying the regulation of OS by circSIPA1L1 and confirmation of whether circSIPA1L1 has a strong connection with the clinical stage of OS would require further investigation.

Conclusions

Our results confirmed circSIPA1L1 expression to be remarkably upregulated in OS cells and tissues. We demonstrated the promotion of OS progression and metastasis by circSIPA1L1 via efficient sponging of miR-411-5p to regulate RAB9A expression, which in turn has been proven to be a driver gene in OS. Our study is the first to identify the role of circSIPA1L1 in OS via the miR-411-5p/RAB9A axis, and hence, might offer a potential biomarker for early diagnosis of OS.

Abbreviations

OS: Osteosarcoma; SIPA1L1: Signal Induced Proliferation Associated 1 Like 1; circRNA: Circular RNA; sh-RNA: Small hairpin RNA; qRT-PCR: Quantitative real-time polymerase chain reaction

Declarations

Ethics approval and consent to participate
All experiments involved in animals were conducted following the guidelines of the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health and ratified by the Ethics Committee of Sir Run Run Shaw Hospital.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The raw data supporting the results of this article will be made accessible by the authors, without undue reservation. The circRNA microarray (GSE96964) analysed during the current study is available in the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/).

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

The research was supported by the National Nature Science Fund of China (grant number 81972504), the Zhejiang Provincial Natural Science Foundation of China (grant number LY19H160058), and the Zhejiang Provincial Natural Science Foundation of China (grant number LY16G030006).

**Authors' contributions**

JJM and SYS conceived of the research. YNX, TY, HNN, YZH and DQ performed the experiments. YNX, TY, HNN and RJZ analyzed the data. JJM and YNX wrote the manuscript. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGEMENTS**

Not applicable.

**References**

1. Ritter J, Bielack SS. Osteosarcoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2010;21 Suppl 7:vii320-5.
2. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nature reviews Cancer. 2014;14(11):722-35.
3. Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert review of anticancer therapy. 2018;18(1):39-50.
4. Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nature reviews Endocrinology. 2017;13(8):480-91.
5. Kumar R, Kumar M, Malhotra K, Patel S. Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment. Current oncology reports. 2018;20(2):13.

6. Du WW, Zhang C, Yang W, Yong T, Awan FM, Yang BB. Identifying and Characterizing circRNA-Protein Interaction. Theranostics. 2017;7(17):4183-91.

7. Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nature reviews Genetics. 2019;20(11):675-91.

8. Patop IL, Wüst S, Kadener S. Past, present, and future of circRNAs. The EMBO journal. 2019;38(16):e100836.

9. Yu T, Wang Y, Fan Y, Fang N, Wang T, Xu T, et al. CircRNAs in cancer metabolism: a review. Journal of hematology & oncology. 2019;12(1):90.

10. Hsiao KY, Sun HS, Tsai SJ. Circular RNA - New member of noncoding RNA with novel functions. Experimental biology and medicine (Maywood, NJ). 2017;242(11):1136-41.

11. Mahmoudi E, Kiltschewskij D, Fitzsimmons C, Cairns MJ. Depolarization-Associated CircRNA Regulate Neural Gene Expression and in Some Cases May Function as Templates for Translation. Cells. 2019;9(1).

12. Li HM, Dai YW, Yu JY, Duan P, Ma XL, Dong WW, et al. Comprehensive circRNA/miRNA/mRNA analysis reveals circRNAs protect against toxicity induced by BPA in GC-2 cells. Epigenomics. 2019;11(8):935-49.

13. Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: From the bench to the clinic. Pharmacology & therapeutics. 2018;187:31-44.

14. Cheng Z, Yu C, Cui S, Wang H, Jin H, Wang C, et al. circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1. Nature communications. 2019;10(1):3200.

15. Lu TX, Rothenberg ME. MicroRNA. The Journal of allergy and clinical immunology. 2018;141(4):1202-7.

16. Yu T, Ma P, Wu D, Shu Y, Gao W. Functions and mechanisms of microRNA-31 in human cancers. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2018;108:1162-9.

17. Yuan Y, Weidhaas JB. Functional microRNA binding site variants. Molecular oncology. 2019;13(1):4-8.

18. Liu H, Xue L, Song C, Liu F, Jiang T, Yang X. Overexpression of circular RNA circ_001569 indicates poor prognosis in hepatocellular carcinoma and promotes cell growth and metastasis by sponging miR-411-5p and miR-432-5p. Biochemical and biophysical research communications. 2018;503(4):2659-65.

19. Sun P, Li L, Li Z. RAB9A Plays an Oncogenic Role in Human Liver Cancer Cells. BioMed research international. 2020;2020:5691671.

20. Mahanty S, Ravichandran K, Chitirala P, Prabha J, Jani RA, Setty SR. Rab9A is required for delivery of cargo from recycling endosomes to melanosomes. Pigment cell & melanoma research.
21. Liu Y, Wang X, Zhang Z, Xiao B, An B, Zhang J. The overexpression of Rab9 promotes tumor progression regulated by XBP1 in breast cancer. OncoTargets and therapy. 2019;12:1815-24.

22. Li R, Jiang J, Shi H, Qian H, Zhang X, Xu W. CircRNA: a rising star in gastric cancer. Cellular and molecular life sciences : CMLS. 2020;77(9):1661-80.

23. Xiong DD, Feng ZB, Lai ZF, Qin Y, Liu LM, Fu HX, et al. High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma. Cell death & disease. 2019;10(9):658.

24. Li Y, Zhao J, Yu S, Wang Z, He X, Su Y, et al. Extracellular Vesicles Long RNA Sequencing Reveals Abundant mRNA, circRNA, and IncRNA in Human Blood as Potential Biomarkers for Cancer Diagnosis. Clinical chemistry. 2019;65(6):798-808.

25. Zhang Z, Yang T, Xiao J. Circular RNAs: Promising Biomarkers for Human Diseases. EBioMedicine. 2018;34:267-74.

26. Arnaiz E, Sole C, Manterola L, Iparraguirre L, Otaegui D, Lawrie CH. CircRNAs and cancer: Biomarkers and master regulators. Seminars in cancer biology. 2019;58:90-9.

27. Wang PJ, Lin ST, Liu SH, Kuo KT, Hsu CH, Knepper MA, et al. Vasopressin-induced serine 269 phosphorylation reduces Sipa1l1 (signal-induced proliferation-associated 1 like 1)-mediated aquaporin-2 endocytosis. The Journal of biological chemistry. 2017;292(19):7984-93.

28. Ge X, Li Z, Zhou Z, Xia Y, Bian M, Yu J. Circular RNA SIPA1L1 promotes osteogenesis via regulating the miR-617/Smad3 axis in dental pulp stem cells. Stem cell research & therapy. 2020;11(1):364.

29. Isobe K, Jung HJ, Yang CR, Claxton J, Sandoval P, Burg MB, et al. Systems-level identification of PKA-dependent signaling in epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(42):E8875-e84.

30. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333-8.

31. Li X, Feng Y, Yang B, Xiao T, Ren H, Yu X, et al. A novel circular RNA, hsa_circ_0030998 suppresses lung cancer tumorigenesis and Taxol resistance by sponging miR-558. Molecular oncology. 2020.